[
  {
    "ts": null,
    "headline": "Personalis price target raised to $8 from $7 at BTIG",
    "summary": "BTIG raised the firm’s price target on Personalis (PSNL) to $8 from $7 and keeps a Buy rating on the shares. The company’s $50M investment from Merck (MRK) strengthens its balance sheet with another strategic partner and represents a major derisking event, the analyst tells investors in a research note. The firm also cites Personalis having extended their contract with Moderna (MRNA), which is now a 10-year contact and has two 5-year renewable options, adding that despite the higher move in the",
    "url": "https://finnhub.io/api/news?id=3749a32f7b1a230d3f9267e720ec0212a66be586fdf2fcdc7710774eaa46c089",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1734784252,
      "headline": "Personalis price target raised to $8 from $7 at BTIG",
      "id": 132097271,
      "image": "",
      "related": "MRNA",
      "source": "Yahoo",
      "summary": "BTIG raised the firm’s price target on Personalis (PSNL) to $8 from $7 and keeps a Buy rating on the shares. The company’s $50M investment from Merck (MRK) strengthens its balance sheet with another strategic partner and represents a major derisking event, the analyst tells investors in a research note. The firm also cites Personalis having extended their contract with Moderna (MRNA), which is now a 10-year contact and has two 5-year renewable options, adding that despite the higher move in the",
      "url": "https://finnhub.io/api/news?id=3749a32f7b1a230d3f9267e720ec0212a66be586fdf2fcdc7710774eaa46c089"
    }
  }
]